2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

904. Outcomes Research: Hemoglobinopathies: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Blood Banking, Treatment Considerations, Drug Development, Biological Therapies, Transfusion, Transplantation, Women’s Health, Adverse Events, Artificial Intelligence (AI), Natural Language Processing, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Quality Improvement, Quality of Care, Diseases, Hemoglobinopathies, Sickle Cell Disease, Myeloid Malignancies, Chronic Myeloid Malignancies, Research, MDS, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Pediatric, Pregnant
PAPER

2674 The psychosocial impact of scleral icterus, a visible sign of sickle cell disease: A social media listening study

Oliver Shastri, MD, Cassandra Trimnell, BA2, Vanessa McWilliams, PharmD3, Laura Galimam4
1 Pfizer Inc., New York, New York, United States
2 Sickle Cell 101, San Jose, California, United States
3 Pfizer Inc., New York, New York, United States
4 Lumanity, London, United Kingdom
INTRODUCTION: Sickle cell disease (SCD) is a hereditary condition that reduces life expectancy and quality of life, affecting ~100,000 people in the United States (US; CDC 2024). Although often considered an invisible illness, SCD is associated with visible signs like jaundice, including eye yellowing or scleral icterus, impaired growth, leg ulcers and scarring (NHS 2022). Scleral icterus is an underrecognized issue for people with SCD (pwSCD), making the underlying condition more visible to others, possibly contributing to stigma and psychological burden (Telfer, et al. Hematol Rep 2018). Online conversations among pwSCD can offer candid insight into health-related concerns and stakeholder perspectives (Healthline Media 2023). Here, we explore these conversations to understand the psychosocial impact of visible symptoms in pwSCD, particularly scleral icterus.

METHODS: This US social media listening (SML) study used a search syntax of keywords/hashtags, public health forums, influencer addresses, and public social media support groups. A search using third-party SML technology (YouScan) captured SCD-related conversations (May 12, 2024-2026) as video transcripts and/or text-based posts/comments across public platforms including: YouTube, Instagram, Facebook, Threads, TikTok, X, Bluesky, and Reddit. SML data were analyzed using machine analytics, manual qualitative analysis, and desk research. A randomized sample was sifted through keyword (visible symptoms), channel filtering, and manual reading, to identify posts meeting inclusion criteria (authored by pwSCD, care partners, or relating to direct patient experience or visible SCD symptoms). Natural Language Processing (NLP) software (Coloop) identified key themes and sentiments. Human-led contextual coding and qualitative analysis validated findings. Here, we report insights from posts mentioning scleral icterus.

RESULTS: Of the total 108,770 posts initially collected, 693 were identified as relevant; these were authored by pwSCD (93%), care partners (1%), or others (6%). Most posts came from TikTok (624), Reddit (38), or Instagram (14). Jaundice-related symptoms generated the most discussion, with scleral icterus mentioned the most (219 posts [31.6%]). Mobility/function loss and skin appearance, notably scarring, were the next most discussed. NLP and qualitative analysis of scleral icterus posts identified three key themes: (1) social perceptions of visible disease, with subthemes of: unwanted attention and intrusive social scrutiny (54.8%), stigma via misidentification (11.9%), and appearance-driven medical invalidation (5.9%); (2) living with a visible identity, with subthemes of: emotional burden and psychological distress (59.8%), disease identity and involuntary disclosure (59.4%), social withdrawal and appearance management (9.1%), and influence on intimate relationships (1.8%); and (3) adaptation and resilience, with the subtheme: reclaiming visibility via advocacy and normalization (50.2%). PwSCD described how yellow eyes cause unsolicited, intrusive social comments yet are dismissed or normalized in healthcare, despite being an SCD hallmark. PwSCD are often stigmatized due to visible symptoms being mistaken for signs of substance/alcohol misuse, liver disease, or other infectious diseases. Posts also reported that scleral icterus causes a great emotional toll, compels involuntary disease disclosure, drives appearance/behavior changes, and impacts confidence in romantic relationships. Importantly, the SCD community is increasingly challenging stigma by raising awareness, sharing lived experiences and promoting acceptance of visible symptoms.

CONCLUSION: This first-of-its-kind study investigates the psychosocial burden of scleral icterus in SCD using SML. Findings confirm that visible symptoms, particularly scleral icterus, contribute to stigma, healthcare dismissal, social withdrawal, and psychological distress. Patient support and disease education should address the clinical, emotional, and social impact of visible symptoms to increase public awareness and acceptance.

 REFERENCES 
1.    CDC. May 2024. https://www.cdc.gov/sickle-cell/data/index.html
2.    NHS. November 2022. https://www.nhs.uk/conditions/sickle-cell-disease/symptoms/ 
3.    Telfer P, et al. Hematol Rep. 2018;10(2):7643. 
4.    Healthline Media. DHC Group. April 2023. https://healthlinemedia.com/assets/files/HealthlineMedia_Social_Health_Trends_Report_2023.pdf

FUNDING 
This study is sponsored by Pfizer
Oliver Shastri, MD: Pfizer Inc. - Stock (publicly traded); Pfizer Inc. - Current Employment